Prestige Biopharma | A Frontier in Biopharmaceuticals
  • Home
  • Group
    • Vision
    • Our Values
    • Prestige Biopharma
    • Prestige Biopharma IDC
  • R&D
    • Innovative Drug
    • Biosimilar
    • Platform Technology
    • Diagnostics
  • IR
    • Stock Information
    • Financials
    • Disclosure Information
    • IR Announcements
  • Media
    • News
    • Brochures
  • Contact
  • English
Select Page

Prestige Biopharma Receives FDA Fast Track Designation for PBP1510 in the Treatment of Pancreatic Cancer

by 김하늘 | Mar 21, 2023 | Uncategorized

Prestige Biopharma has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for PBP1510 (International Non-proprietary name: Ulenistamab), in the treatment of unresectable or metastatic pancreatic adenocarcinoma (PDAC) that has relapsed...

Recent Posts

  • Prestige Biopharma Receives FDA Fast Track Designation for PBP1510 in the Treatment of Pancreatic Cancer
  • Prestige Biopharma Requests FDA Fast Track Designation for Its First-in-Class Pancreatic Cancer Treatment PBP1510
  • Final Analysis of Phase 3 Clinical Trial of Prestige Biopharma’s HD201 published in ‘BMC Cancer’

Recent Comments

No comments to show.

Archives

  • March 2023
  • February 2023

Categories

  • Uncategorized

Copyright © 2026 Prestige Biopharma Limited. All Rights Reserved. 

Connect with us on LinkedIn｜YouTube
Data Policy